Staying Connected Between Visits: A Sustainable Model for Remote Monitoring

Oncology Issues
February 2026
Volume 41
Issue 1

Cancer care does not pause when a patient leaves the clinic. For many patients with cancer, especially those actively receiving treatment, the hardest hours can arrive quietly at home, when new pain develops, fatigue becomes overwhelming, or social-related needs begin to affect care.

When issues arise, patients often hesitate to reach out to their care teams. Some worry about overreacting; others don’t want to “bother” their care team. Many feel uncertain about what’s normal during treatment or feel uncomfortable calling. In fact, study data show that as few as 10% of patients with cancer call before going to the emergency department.1 As a result, symptoms that begin as subtle changes can escalate into urgent situations before clinicians even know they exist.

Silence, in oncology, can be the most dangerous symptom. Patients do not always know when something is serious, and many simply do not want to burden the team. At Highlands Oncology, one of the largest independent oncology practices in Arkansas, we needed a way to hear from patients sooner—before a quiet concern turned into a crisis. Our journey began years before remote patient monitoring became mainstream in community oncology, driven by the belief that technology, when implemented thoughtfully, can break down barriers to between-visit care.

The Promise of Remote Symptom Monitoring

Remote monitoring through electronic patient-reported outcomes (ePROs) offers a structured way for patients to share symptoms they experience in real time through digital tools. When integrated into triage workflows, ePROs can help triage nurses intervene early and catch problems before they become bigger issues.

Evidence supporting the clinical impact of ePROs is strong. In landmark randomized studies, Ethan Basch, MD, MSc, FASCO, demonstrated that routine symptom reporting during cancer treatment led to:

• Improved quality of life

• Fewer emergency department visits and hospitalizations

• Longer time on treatment

• Improved overall survival by 20%.2-4

These findings established a compelling clinical truth: When oncology teams hear from patients between visits and can proactively respond, patient outcomes improve.

For Highlands, this finding aligned with an existing philosophy. “When patients are struggling at home, we need to know—not after the fact,” Hughes shared. “Remote monitoring offered a real path to delivering on that need at scale.”

Launching Remote Monitoring During the Oncology Care Model

Highlands first implemented remote symptom monitoring during the Oncology Care Model (OCM) to reduce avoidable hospital utilization and improve patient-centered care.

In June 2020, Highlands partnered with Canopy, a leader in enterprise artificial intelligence (AI) for oncology, to implement an ePRO program across 3 sites. The care teams at Highlands partnered closely with Canopy to embed reporting and triage decision support directly into clinical workflows. Staff training occurred on site, and Canopy team members joined daily huddles to iterate in real time on workflows, dashboards, and nurse triage pathways.

Enrollment began at infusion check-in and later expanded to “chemo class,” where new patients learned how to download the app, complete a practice submission, and understand when to report symptoms. A blended model supported patient preferences, offering mobile app, web, and interactive voice response options.

This collaborative approach ensured the program worked for patients and for the nurses delivering care. As Highlands rolled out the model, digital symptom reports were routed to a centralized triage team, auto prioritized based on clinical severity and guided by standardized triage pathways, which enabled timely intervention without adding another manual inbox.

“It took a lot of teamwork, but [members of] the Canopy team were on site with us,” said Tracy Thurow, RN, OCN. “They incorporated our needs and the needs of our patients into their technology, while taking into consideration our workflows.”

From day one, the program was designed not as a standalone initiative, but as a new foundation for patient support. When OCM ended, Highlands didn’t scale back, it expanded.

“We had transformed,” said Jeff Hunnicutt, CEO of Highlands Oncology. “You can’t un-transform. This is the way we care for patients now.”

Real-World Results at Scale

Since the launch in 2020, Highlands Oncology has expanded remote monitoring to thousands of patients across infusion and oral therapies, including bispecific antibodies and other emerging regimens.

Patient engagement

  • 3800 patients enrolled in first year5
  • Approximately 60% of patients on therapy actively enrolled today5
  • Approximately 800 symptom reports weekly at scale5
  • 1857 patients on oral anti-cancer medications enrolled in 3 months11
  • 88% of patients engaging twice monthly at 6 months.6

Clinical outcomes

  • 22% reduction in emergency department visits and hospitalizations (American Society of Clinical Oncology (ASCO) meeting 2022)7
  • 45% increase in treatment persistence at 3 months (ASCO 2022)8
  • 37% reduction in discontinuation at 3 months (American Society of Hematology (ASH) meeting 2024)9
  • Earlier recognition of inflammatory toxicities in bispecific therapy (ASH 2024).10

Operational efficiency

  • Approximately 19-minute average time to resolution for symptom reports5
  • 89% issue resolution rate across all ticket types with patient messaging, compared with 75% with prior workflows.5

Highlands Oncology also participated in a study evaluating remote therapeutic monitoring to reduce hospitalizations due to infection in patients being treated for hematologic malignancies, whose findings were selected for oral presentation at the 2025 ASH Annual Meeting and Exposition in December.12

Sustaining Continuous Care With Remote Therapeutic Monitoring

Because Highlands saw remote support as essential to patient well-being, leadership prioritized long-term sustainability through alternative reimbursement programs.

When OCM ended, the practice adopted Chronic Care Management (CCM) and later integrated remote therapeutic monitoring (RTM) to support structured outreach, symptom review, and follow-up.

“Integrating ePROs with programs like CCM and RTM builds a sustainable model that improves outcomes, eases staff workload, and generates revenue to reinvest in between-visit care,” said Hunnicutt.

Today, the program generates around $1 million in annual recurring revenue to reinvest directly into nursing resources and supportive care infrastructure.5

AI and the Future of Remote Monitoring

As Highlands Oncology’s remote care program continues to grow, the focus has shifted to scaling responsibility. Automation and AI features through Canopy help streamline predictable, manual tasks and lighten the load for nurses and nonclinical staff alike.

To support growth without increasing administrative burden, Highlands incorporated:

• Digital enrollment workflows for ePROs

• Smart reporting reminders • Decision support and autocharting

• AI-assisted patient messaging across patient services (eg, scheduling).

Technology will never replace clinical expertise. But it can help direct that expertise to the right moments.

Next, Highlands will pilot an agentic after-hours phone center, offering patients real-time support outside clinic hours while ensuring overnight needs are routed appropriately and nurses receive actionable tickets when they return.

Through thoughtful use of automation and cross-team coordination, Highlands Oncology is creating a sustainable, patient-centered model for remote monitoring.

Lauren Hughes, RN is the director of Infusion Services at Highlands Oncology in Springdale, Arkansas.

References

  1. Kolodziej M, Hoverman JR, Garey JS, et al. Benchmarks for value in cancer care: an analysis of a large commercial population. J Oncol Pract. 2011;7(5):301-306. doi: 10.1200/JOP.2011.000394
  2. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557-565. doi:10.1200/ JCO.2015.63.0830
  3. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197-198. doi:10.1001/ jama.2017.7156
  4. Basch E, et al. Patient-reported outcomes to improve cancer care. ASCO Educ Book. 2018;38:225-235.
  5. Canopy internal analysis of partnership data
  6. Cherny NI, Parrinello CM, Kwiatkowsky L, et al. Feasibility of large-scale implementation of an electronic patient-reported outcome remote monitoring system for patients on active treatment at a community cancer center. JCO Oncol Pract. 2022;18(12):e1918-e1926. doi:10.1200/ OP.22.00180
  7. Kolodziej MA, Kwiatkowsky L, Parrinello C, et al. ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. J Clin Oncol. 2022;40(suppl 16):1508. doi:10.1200/JCO.2022.40.16_suppl.1508
  8. Parrinello C, Calkins G, Kwiatkowsky L, et al. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. J Clin Oncol. 2022;40(suppl 16):1528. doi:10.1200/JCO.2022.40.16_suppl.1528
  9. Essell JH, Derman BA, Kolodziej MA, et al. Symptoms detection among patients with lymphoid malignancies (LM) using electronic patient-reported outcomes (ePROs) in community hematology-oncology clinics. Blood. 2024;144(suppl 1):3756. doi:10.1182/blood-2024-204413
  10. Derman BA, Essell JH, Kolodziej MA, et al. Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. Blood. 2024;144(suppl 1):5046. doi:10.1182/ blood-2024-206505
  11. Sharma S, Doshi GK, Shumway NM, et al. Application of the remote therapeutic monitoring (RTM) platform to optimize adherence and manage toxicity of oral anti-cancer medications (OAM). JCO Oncol Pract. 2025;21(suppl 10):594. doi:10.1200/OP.2025.21.10_suppl.594
  12. Essell J, Ascha M, Schaefer E, et al. Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy. Blood. 2025;146(suppl 1):131. doi:10.1182/ blood-2025-131

Upcoming Events

ACCC Oncology Reimbursement Meeting | Providence

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,
Virtual ORM | Winter 2026

Virtual ORM | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington